Abstract
Potent adenosine hA2A receptor antagonists are often accompanied by poor aqueous solubility, which presents issues for drug development. Herein we describe the early exploration of the structure-activity relationships of a lead pyrimidin-4-yl acetamide series to provide potent and selective 2-amino-N-pyrimidin-4-yl acetamides as hA2A receptor antagonists with excellent aqueous solubility. In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A2A receptor versus the human A2A receptor.
MeSH terms
-
Acetamides / chemical synthesis*
-
Acetamides / pharmacokinetics
-
Acetamides / pharmacology
-
Adenosine A2 Receptor Antagonists*
-
Animals
-
Antiparkinson Agents / chemical synthesis*
-
Antiparkinson Agents / pharmacokinetics
-
Antiparkinson Agents / pharmacology
-
Catalepsy / chemically induced
-
Catalepsy / psychology
-
Cell Line
-
Cloning, Molecular
-
Cricetinae
-
Cricetulus
-
Haloperidol
-
Humans
-
In Vitro Techniques
-
Male
-
Microsomes, Liver / metabolism
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / pharmacology
-
Radioligand Assay
-
Rats
-
Rats, Wistar
-
Reaction Time / drug effects
-
Receptor, Adenosine A2A / genetics
-
Solubility
-
Structure-Activity Relationship
-
Water
Substances
-
Acetamides
-
Adenosine A2 Receptor Antagonists
-
Antiparkinson Agents
-
Pyrimidines
-
Receptor, Adenosine A2A
-
Water
-
Haloperidol